HER2阳性晚期乳腺癌与肺癌 命运

ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancers: Reporting from the ESMO Congress 2021, Michail Ignatiadis discusses results from the DESTINY-Breast03 and DESTINY-Lung1 studies performed in the metastatic setting and testing the efficacy and safety.